MetaCap

Cue Biopharma (CUE) vs MindWalk (HYFT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MindWalk (HYFT) has outperformed Cue Biopharma (CUE) over the past year, losing 59.0% versus a loss of 76.8%. Over five years, HYFT leads with a -89.3% price change compared with -98.9% for CUE. Cue Biopharma is the larger company by market cap ($34.7 million vs $32.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CUE-76.75%HYFT-59.02%
+122%+14%-94%
Nov 21, 20251 yearNov 20, 2026
CUE-99.07%HYFT-87.65%
+22%-42%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CUE versus HYFT key metrics
MetricCUEHYFT
Share price$4.15$0.6844
Market cap$34.69M$32.56M
1-day change-7.78%-14.27%
YTD return-54.64%-62.40%
1-year return-76.75%-59.02%
5-year return-98.92%-89.34%
EPS (TTM)$-27.80$-0.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$27.47M—
Revenue growth (YoY)+195.75%—
Net income (latest FY)$-26.60M—
Operating margin-96.67%—
Net margin-96.85%—
52-week high$45.50$2.99
52-week low$2.83$0.64
Distance from 52-week high-90.88%-77.11%
Analyst consensusnonenone
Avg. price target upside+2020.48%+532.67%
Average volume567.02K257.86K
Shares outstanding8.36M47.57M
Employees2974
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HYFT has outperformed CUE by 17.7 percentage points over the past year.

About Cue Biopharma

CUE stock →

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About MindWalk

HYFT stock →

MindWalk Holdings Corp. operates as a bio-native AI company.

Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees

CUE vs HYFT FAQ

Which is bigger, Cue Biopharma or MindWalk?

Cue Biopharma (CUE) is larger, with a market capitalization of $34.69M compared with $32.56M for MindWalk (HYFT).

Which stock has performed better over the past year, CUE or HYFT?

HYFT returned -59.02% over the past 12 months, compared with -76.75% for CUE (price return, excluding dividends). Past performance does not predict future results.

Are Cue Biopharma and MindWalk in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons